ADC Therapeutics (NYSE:ADCT), a Swiss and US late clinical-stage oncology-focused biotechnology company, raised $267.6m through its IPO.

ADC has its head office in Epalinges, Switzerland, Research and Preclinical Development in London, UK, Clinical, Commercial and US Operations in New Providence, NJ, and Chemistry, Manufacture and Control offices in San Mateo, CA. Source FINSMES 5/7/2020